Movement Alert|Eli Lilly Rises 3.08% in Pre-Market Trading, Multiple Banks Raise Target Prices as Mounjaro Gains Pediatric Approval in Canada

Market Focus
Jul 07

On July 7, Eli Lilly rose 3.08% in pre-market trading, trading at $1,235.0/share, with turnover of $22.23 million.

On the news front, JPMorgan raised its target price on Eli Lilly from $1,300 to $1,400, implying approximately 17% upside from the current level. Analyst Chris Schott expects total quarterly sales of approximately $20.7 billion and EPS of $8.85, both above consensus estimates, driven by Mounjaro's continued international volume growth and steady U.S. obesity market expansion. Cantor Fitzgerald also lifted its target from $1,230 to $1,350.

Additionally, Health Canada approved Mounjaro (tirzepatide) for the treatment of type 2 diabetes in pediatric patients aged 10 and older, further broadening the drug's addressable population. The company's next earnings report is scheduled for August 5, with consensus EPS expected at $8.98.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10